Clone mrq28

Manufactured by Cell Marque

Sourced in United States

Clone MRQ28 is a monoclonal antibody produced for research use. It is intended for the detection of a specific antigen target.

Automatically generated - may contain errors

Lab products found in correlation

Clone 44, by Cell Marque (3 mentions) Clone 138g6, by Cell Signaling Technology (3 mentions) Clone 4b5, by Roche (3 mentions) Clone m1, by Roche (3 mentions) Clone g219 1129, by Roche (2 mentions) Ep38y, by Abcam (2 mentions) Clone sp44, by Roche (2 mentions) Clone 44, by BD (1 mentions) Eber probe, by Leica (1 mentions) Clone g168 15, by BD (1 mentions) Bondmax detection system, by Leica (1 mentions) Zytodot 2c spec met cen7 probe, by ZytoVision (1 mentions) Zytodot 2c cish implementation kit, by ZytoVision (1 mentions) Clone ep38y, by Abcam (1 mentions) Clone do 7, by Leica (1 mentions) G219 1129, by Roche (1 mentions) Ish iview kit, by Roche (1 mentions)

4 protocols using clone mrq28

Comprehensive Tumor Biomarker Profiling

Cited 5 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

The HER2-and MET-status was assessed as previously described [11] (link), [12] (link), [16] (link), [17] (link), [18] (link) using immunohistochemistry [anti-Her2/neu antibody; clone SP3, Thermo Fisher Scientific; Fremont; USA (#MA5-14509); anti-MET antibody; clone SP44; Spring Bioscience; Pleasanton, California, USA (#M3444)] and in situ–hybridization [ZytoDot 2C SPEC HER2/CEN17 Probe (#C-3032-400), ZytoDot 2C SPEC MET/CEN7 Probe (#C-3057-400) and the ZytoDot 2C CISH Implementation Kit (#C-3044-40); ZytoVision GmbH, Bremerhaven, Germany)]. Epstein–Barr virus (EBV)–encoded RNA was detected using the EBER-probe (Novocastra, Leica Microsystems GmbH, Nussloch, Germany; #PB0589) and the BondMax-detection system according to the manufacturer's instructions (Leica Microsystems GmbH). MSI status was assessed by immunostaining using antibodies directed against MLH1 (clone G168-15, BD Biosciences, Heidelberg, Germany; #MA1-25669), PMS2 (clone MRQ-28; Cell Marque Corporation, Rocklin, USA; #288M-16-ASR), MSH2 (clone FE11; Calbiochem, Merck KGaA, Darmstadt, Germany; #MABE284), and MSH6 (clone 44, BD Biosciences; #610919) as well as by comparison of the allelic profiles of the mononucleotide repeat markers BAT-25, BAT-26, NR-21, NR-24, and NR-27 in tumor and corresponding normal tissue in cases with ambiguous immunostaining [16] (link).

Schoop H., Bregenzer A., Halske C., Behrens H.M., Krüger S., Egberts J.H, & Röcken C. (2019). Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors—Comparison Against a Therapy Naïve Cohort. Translational Oncology, 13(2), 165-176.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Cancer Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry (IHC) was performed using a Ventana XT automated stainer (Ventana) with antibodies for MutL homolog 1 (MLH1, ready to use, clone M1, Roche, Basel, Switzerland), MutS protein homolog 2 (MSH2, ready to use, clone G219-1129; Roche), MutS homolog 6 (MSH6, 1:100, clone 44; Cell Marque, Rocklin, CA, USA), postmeiotic segregation increased 2 (PMS2, 1:40, clone MRQ28; Cell Marque), epidermal growth factor receptor 2 (HER2, ready to use, clone 4B5; Roche), MET (ready to use, clone SP44; Roche), epidermal growth factor receptor (EGFR, 1:100, clone EP38Y; Abcam, Cambridge, UK), phosphatase and tensin homolog (PTEN, 1:100, clone 138G6; Cell Signaling, Danvers, MA, USA), and p53 (1:300, clone DO7; Novocastra, Newcastle, UK). IHC was performed in all cases as previously described [14] .

Woo H.Y., Bae Y.S., Kim J.H., Lee S.K., Lee Y.C., Cheong J.H., Noh S.H, & Kim H. (2017). Distinct expression profile of key molecules in crawling-type early gastric carcinoma. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 20(4).

+ Open protocol

+ Expand

Immunohistochemical Staining Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was performed with a Ventana XT automated staining instrument. Antibodies recognizing the following targets were used: MutL homolog 1 (MLH1, ready to use, clone M1, Roche, Basel, Schweiz), MutS protein homolog 2 (MSH2, ready to use, clone G219-1129, Roche), MutS homolog 6 (MSH6, 1:100, clone 44, Cell Marque, Rocklin, CA), postmeiotic segregation increased 2 (PMS2, 1:40, clone MRQ28, Cell Marque), HER2 (ready to use, clone 4B5, Roche), EGFR (1:100, EP38Y, Abcam, Cambridge, UK), c-MET (ready to use, clone SP44, Roche), PTEN (1:100, clone 138G6, Cell signaling, Danvers, MA), and p53 (1:300, DO7, Novocastra, Newcastle, UK). Sections were deparaffinized using EZ Prep solution (Ventana Corporation, Tucson, AZ). CC1 standard (pH 8.4 buffer containing Tris/borate/EDTA) was used for antigen retrieval and blocked with inhibitor D (3% H₂O₂) for 4 min at 37°C. Slides were incubated with primary antibody for 40 min at 37°C, followed by a universal secondary antibody for 20 min at 37°C. Slides were incubated in streptavidin-horseradish peroxidase (SA-HRP) D for 16 min at 37°C, after which the substrate, 3,3′-diaminobenzidine tetrahydrochloride (DAB) H₂O₂, was added for 8 min, followed by hematoxylin and bluing reagent counterstaining at 37°C.

Kim H.S., Shin S.J., Beom S.H., Jung M., Choi Y.Y., Son T., Kim H.I., Cheong J.H., Hyung W.J., Noh S.H., Chung H., Park J.C., Shin S.K., Lee S.K., Lee Y.C., Koom W.S., Lim J.S., Chung H.C., Rha S.Y, & Kim H. (2016). Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget, 7(28), 44608-44620.

+ Open protocol

+ Expand

Immunohistochemistry Profiling of Biomarkers

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was performed on a Ventana XT automated staining instrument (Ventana Medical Systems, Tucson, AZ, USA). The following target-specific antibodies were used according to the manufacturer's instructions and a previous study [20 (link)]: MutL homolog 1 (MLH1, ready to use, clone M1, Roche, Basel, Switzerland), MutS protein homolog 2 (MSH2, ready to use, clone G219-1129, Roche), MutS homolog 6 (MSH6, 1:100, clone 44, Cell Marque, Rocklin, CA, USA), postmeiotic segregation increased 2 (PMS2, 1:40, clone MRQ28, Cell Marque), ERBB2 (ready to use, clone 4B5, Roche), EGFR (1:100, EP38Y, Abcam, Cambridge, UK), c-MET (ready to use, clone SP44, Roche), PTEN (1:100, clone 138G6, Cell Signaling, Danvers, MA, USA), and p53 (1:300, DO7, Novocastra, Newcastle, UK). Epstein-Barr virus-encoded small RNAs (EBER) in situ hybridization (ISH) was performed using a Ventana Benchmark ISH system and ISH iView kit (Ventana Medical Systems, Tucson, AZ, USA).

Kim H.S., Lee H., Shin S.J., Beom S.H., Jung M., Bae S., Lee E.Y., Park K.H., Choi Y.Y., Son T., Kim H.I., Cheong J.H., Hyung W.J., Park J.C., Shin S.K., Lee S.K., Lee Y.C., Koom W.S., Lim J.S., Chung H.C., Noh S.H., Rha S.Y., Kim H, & Paik S. (2017). Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Oncotarget, 8(24), 38389-38398.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!